We also tested our extended signature against a proinflammatory monocyte/macrophage signature proposed by single-cell RNA sequencing of the immune cell infiltrate in melanoma [56], and against a shortened signature that identifies the claudin-low BRCA subtype, based on loss of claudins 3, 4, and 7 and other adhesion genes (marked with an asterisk in Figure 5A) and gain of mesenchymal genes [57]. This evidence concerns the gene CLDN3 and melanoma.